台灣2025年C肝消除的策略與進度

Eliminating hepatitis C in Taiwan by 2025: strategies and progress

10.6288/TJPH.202102_40(1).PF01

吳慧敏(Grace Hui-Min Wu)；楊雯雯(Wen-Wen Yang)；劉嘉玲(Chia-Ling Liu)；鄭國本(Kuo-Pen Cheng)；陳時中(Shih-Chung Chen)；陳建仁(Chien-Jen Chen)；蒲若芳(Raoh-Fang Pwu)

台灣公共衛生雜誌

40卷1期（2021 / 02 / 26）

1 - 4

繁體中文

1. CDA Foundation. Polaris-Hep C. Available at: http://cdafound.org/polaris/. Accessed February 18, 2021.
2. Chen, CJ,Chuang, WL,Lee, MH(2016).Disease burden of chronic hepatitis C virus (HCV) infection in Taiwan.The 25th Asian Pacific Association for the Study of the Liver (APASL),Japan: Tokyo:
3. Chen, DS(2019).Taiwan commits to eliminating hepatitis C in 2025.Lancet Infect Dis,19,466-467.
4. Chen, TZ,Wu, JC,Yen, FS(1995).Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan.J Med Virol,46,247-251.
5. Chiang, CJ,Yang, YW,Chen, JD(2015).Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan.Hepatology,61,1154-1162.
6. Chiang, CJ,Yang, YW,You, SL,Lai, MS,Chen, CJ(2013).Thirty-year outcomes of the national hepatitis Bimmunization program in Taiwan.JAMA,310,974-976.
7. Cox, AL,El-Sayed, MH,Kao, JH(2020).Progress towards elimination goals for viral hepatitis.Nat Rev Gastroenterol Hepatol,17,533-542.
8. Ho, MS,Hsu, CP,Yuh, Y(1997).High rate of hepatitis C virus infection in an isolated community: persistent hyperendemicity or period-related phenomena?.J Med Virol,52,370-376.
9. Huang, MH,Chang, SY,Liu, CH(2019).HCV reinfections after viral clearance among HIV-positive patients with recent HCV infection in Taiwan.Liver Int,39,1860-1867.
10. Li, CW,Yang, CJ,Sun, HY(2018).Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.PLoS One,13,e0194149.
11. Liu, CH,Liu, CJ,Lin, CL(2008).Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.Clin Infect Dis,47,1260-1269.
12. Liu, JY,Lin, HH,Liu, YC(2008).Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan.Clin Infect Dis,46,1761-1768.
13. Ng, MH,Chou, JY,Chang, TJ(2013).High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan.Addict Behav,38,2089-2093.
14. Razavi, H,Gonzalez, YS,Yuen, C,Cornberg, M(2020).Response to Taiwan is on track of accelerating hepatitis Celimination by 2025.Liver Int,40,1507.
15. Razavi, H,Sanchez Gonzalez, Y,Yuen, C,Cornberg, M(2020).Global timing of hepatitis C virus elimination in high-income countries.Liver Int,40,522-529.
16. Sun, CA,Chen, HC,Lu, SN(2001).Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors.J Med Virol,65,30-34.
17. Wang, CS,Chang, TT,Chou, P(1998).Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan.J Clin Epidemiol,51,733-738.
18. Wang, JT,Wang, TH,Lin, JT,Lee, CZ,Sheu, JC,Chen, DS(1995).Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan.J Gastroenterol Hepatol,10,454-458.
19. WHO.Global health sectors strategy on viral hepatitis 2016-2021: towards ending viral hepatits.
20. Wu, GHM,Pwu, RF,Chen, SC(2018).Achieving hepatitis C elimination in Taiwan - overcoming barriers by setting feasible strategies.J Formos Med Assoc,117,1044-1045.
21. Wu, GHM,Pwu, RF,Chen, SC,Chen, DS(2020).Taiwan is on track of accelerating hepatitis C elimination by 2025.Liver Int,40,1506-1507.
22. Yu, ML,Dai, CY,Huang, JF(2007).A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.Gut,56,553-559.
23. Yu, ML,Dai, CY,Huang, JF(2008).Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Hepatology,47,1884-1893.
24. 劉嘉玲, CL,楊雯雯, WW,吳慧敏, GHM,鄭國本, KP,蒲若芳, RF(2019)。台灣C型肝炎消除的國家政策與軌跡。愛之關懷季刊，109，6-16。
25. 衛生福利部, R.O.C. (Taiwan)(2019).國家消除C肝政策綱領2018-2025.台北=Taipei:衛生福利部=Ministry of Health and Welfare, R.O.C. (Taiwan).
26. 衛生福利部：國家消除C肝辦公室統計資訊。https://www.mohw.gov.tw/lp-4465-1.html。引用2021/02/18。 Ministry of Health and Welfare, R.O.C. (Taiwan). The statistics information of Taiwan National Hepatitis C Program Office. Available at: https://www.mohw.gov.tw/lp-4465-1.html. Accessed February 18, 2021. [In Chinese]

1. 簡榮南,盧勝男,鄭國本,劉嘉玲,蒲若芳,楊雯雯,吳慧敏(2023)。推動消除C肝政策之回顧。台灣公共衛生雜誌，42(2)，165-179。
2. 鍾安妮,鍾宇筑,陳為堅,林佩萱,王聲昌(2022)。消除C型肝炎最關鍵的一哩路：注射藥物族群的防治現況與建議。台灣公共衛生雜誌，41(5)，479-482。